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Abstract
Background: There are two ways to open the abdominal cavity in elective general surgery:
vertically or transversely. Various clinical studies and a meta-analysis have postulated that the
transverse approach is superior to other approaches as regards complications. However, in a
recent survey it was shown that 90 % of all abdominal incisions in visceral surgery are still vertical
incisions. This discrepancy between existing recommendations of clinical trials and clinical practice
could be explained by the lack of acceptance of these results due to a number of deficits in the
study design and analysis, subsequent low internal validity, and therefore limited external
generalisability. The objective of this study is to address the issue from the patient's perspective.
Methods: This is an intraoperatively randomized controlled observer and patient-blinded two-
group parallel equivalence trial. The study setting is the Department of General-, Visceral-, Trauma
Surgery and Outpatient Clinic of the University of Heidelberg, Medical School. A total of 172
patients of both genders, aged over 18 years who are scheduled for an elective abdominal
operation and are eligible for either a transverse or vertical incision. To show equivalence of the
two approaches or the superiority of one of them from the perspective of the patient, a primary
endpoint is defined: the pain experienced by the patient (VAS 0–100) on day two after surgery and
the amount of analgesic required (piritramide [mg/h]). A confidence interval approach will be used
for analysis. A global α-Level of 0.05 and a power of 0.8 is guaranteed, resulting in a size of 86
patients for each group. Secondary endpoints are: time interval to open and close the abdomen,
early-onset complications (frequency of burst abdomen, postoperative pulmonary complications,
and wound infection) and late complications (frequency of incisional hernias). Different outcome
variables will be ranked by patients and surgeons to assess the relevance of possible endpoints from
the patients' and surgeons' perspective.
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to answer the question if the transverse abdominal incision is equivalent to the vertical one due to
the described endpoints.
Background
The choice of surgical incision to open the abdominal cav-
ity can be based on patient, surgeon, or health care system
criteria. From a patient's point of view pain and restriction
of ingestion are important [1]. Considering prior surgical
studies, these probable main interests of patients have not
been examined systematically [2-8]. Surgeons' main inter-
ests, aside from the quick and optimal exposure of the
operative field, are: time to open and close the abdomen
and frequency of burst abdomen, wound infection, post-
operative pulmonary complications, and incisional her-
nias [2-8]. For health economy, parameters such as
duration of operation, length of hospital stay, and full
physical and mental activity are relevant [9].
The results of a number of prior randomized controlled
studies (RCT) [2-8] and a meta-analysis [9] in this field
have shown the transverse approach to be superior to
other incisions as regards complications. However, in sur-
gical practice the midline incision is still mainly used [10].
One reason for this discrepancy may be the deficits in
study design of these trials, reducing their internal valid-
ity. Main problems are: underpowered studies (sample
size too small) to estimate the real difference sufficiently,
lack of standardization and/or missing data for the surgi-
cal technique of the abdominal wall closure [5,9,11], no
blinding of patients and assessors [2,3], study inhomoge-
neities in the meta-analysis [9], and lack of standardized
postoperative analgesia and postoperative treatment
[9,12,13].
The one available meta-analysis [9] concludes that the
transverse incision is superior to the midline incision,
leading to a reduction in early-onset complications (burst
abdomen, pulmonary disorders) and late complications
(incisional hernia) that is attributed to anatomical and
physiological advantages. However, the occurrence of
these complications not only depends on the type of inci-
sion but also on the closure technique. The studies
included were retrieved in their original form and exam-
ined again separately according to their endpoints. Only
one RCT focussed on the frequency of burst abdomen and
could not find an advantage for the transverse approach
[2]. Pulmonary early-onset complications were assessed
in a RCT and were equally distributed in both groups [3].
None of the reviewed studies showed a significant differ-
ence in the occurrence of wound infections [9]. In the
original data of Greenall et al. [2] the number of inci-
sional hernias is similar with both approaches. Further-
more, retrospective and prospective study data were
pooled in the meta-analysis [9] and led subsequently to a
non-conclusive result.
To date, no clear evidence exists that the transverse inci-
sion is superior to other incisions for the endpoints early
and late postoperative complications. It is therefore justi-
fied to focus on such a comparison from the patient's per-
spective. To do this in a scientifically valid manner, a
randomized controlled observer and patient-blinded
study is required under standardized conditions for the
closure technique, pain therapy, and postoperative
treatment.
The purpose of this trial is to show that there is no signif-
icant difference in pain intensity as experienced by the
patient or in the amount of piritramide required between
the two abdominal incisions, assuming similar complica-
tion rates. Additionally, early and late postoperative com-
plications will be assessed for a follow-up time of 1 year.
Methods
Study Objectives
The primary objective of this study is to compare the
transverse and the vertical abdominal approach under
consideration of the abdominal pain intensity experi-
enced by a patient and the amount of analgesic drugs used
in a number of common surgical procedures.
The primary endpoint is the abdominal pain intensity
experienced by a patient, quantified with the Visual Ana-
logue Scale (VAS), and the amount of analgesic required
(piritramide [mg/h]) on the second postoperative day.
Secondary objectives are the frequencies of early- and late-
onset complications such as burst abdomen, postopera-
tive pulmonary complications, wound infections and
incisional hernias (as given in Table 1). In addition, pain
is quantified according to the Pain-Sensation-Scale by
Geissner, a modified McGill Pain Questionnaire,
designed for studies conducted in Germany [14]. To assess
the relevance of the possible endpoints from the patient's
and surgeon's perspective, the following aspects are
ranked from 1 (= most important) to 9 (= least important)
by patients and surgeons: postoperative complication,
intraoperative complication, duration of hospital stay,
starting with standard enteral nutrition, death, postopera-
tive pain, postoperative fatigue, restoration of complete
physical maximum resilience, and cosmetic result [1]. ThePage 2 of 7
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Patients rank the aspects twice: once at inclusion and
again at discharge to investigate whether their main peri-
operative interest changes during the hospital stay.
Design of Study
A controlled intraoperatively randomized observer and
patient-blinded trial has been deemed appropriate. A par-
allel group equivalence design was selected because,
based on prior studies and knowledge, great differences
cannot be expected. The randomization is stratified
according to the type of operation planned.
Setting
The setting of the study is the Department of General-, Vis-
ceral-, Trauma Surgery and Outpatient Clinic of the Uni-
versity of Heidelberg, Medical School.
Participants
A total of 172 patients over 18 years will be included who
are scheduled for an elective abdominal operation and are
eligible for either a transverse or vertical incision.
Eligibility criteria
Inclusion Criteria
• Age equal or greater than 18 years
• Expected survival time more than 12 months
• Patients scheduled for the following procedures:
1. Whipple procedure (classic or pylorus-preserving)
2. Duodenum-preserving resection of the pancreatic head
3. Gastrectomy (partial or total gastrectomy)
4. Colon resection (left or right or transverse / classic or
extended)
5. Ileocecal resection
• Primary and elective laparotomy
• Patient must be able to give informed consent
• Patient has given informed consent
Exclusion Criteria
• Permanent therapy with a opioid equivalent drug for
any reason within 12 months before operation (duration
longer than 2 weeks)
• Incompatibility of metamizole
• Recurrent opening of the abdominal cavity (not laparo-
scopic appendectomy, laparoscopic cholecystectomy,
laparoscopic adrenalectomy, diagnostic laparoscopy or
appendectomy), including prior cesarean section and
Pfannenstiel incision (e.g., hysterectomy)
• Participation in another intervention trial that would
interfere with the intervention and outcome of this study
• Severe psychiatric or neurologic diseases
• Lack of compliance
• Drug and/or alcohol abuse according to local standards
• Current immunosuppressive therapy (more than 40 mg
of a corticoid per day or azathioprine)
• Chemotherapy within 2 weeks before operation
• Radiotherapy of the abdomen completed longer than 8
weeks before operation (except for neoadjuvant therapy,
e.g., for pancreatic cancer)
• Liver, gallbladder, spleen, and rectum surgery
Table 1: Definition of early-onset and late complications
Complication Definition
Burst abdomen Postoperatively missing continuity of the abdominal fascia in combination with a wound dehiscence with 
subsequent relapse operation.
Wound infection Redness, wound dehiscence with secretion either of putrid or caliginous, smelly fluid or requiring 
antibiotic treatment or surgical intervention.
Postoperative pulmonary complications Infection of the lung with either evidence of increased infection parameters (CRP > 2 mg/dl and/or 
leukocytes > 10 0000/ml) that are not caused by a different pathologic process or evidence of 
pulmonary infiltration in the chest x-ray requiring antibiotic therapy.
Incisional hernia Postoperative evidence of a fascia dehiscence after completed superficial wound healing with or 
without prolapse of abdominal organs, confirmed by abdominal sonography.Page 3 of 7
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The final protocol was approved by the independent eth-
ics committee of the University of Heidelberg, Medical
School. Informed consent will be obtained from the
patient in oral and written form before inclusion in the
trial.
Safety
Burst abdomen, pulmonary infection, and wound infec-
tion are secondary endpoints, but are also defined as
adverse events. Burst abdomen and postoperative pulmo-
nary infection will even always be considered a serious
adverse event. The term adverse event covers any sign,
symptom, syndrome, or illness that appears or worsens in
a patient during the period of observation in the clinical
trial and that may impair the well-being of the patient.
The term also covers laboratory findings or results of other
diagnostic procedures that are considered to be clinically
relevant. A serious adverse event is any adverse event that
occurs at any time during the period of observation that
results in death, is immediately life-threatening, requires
or prolongs hospitalization, or results in persistent or sig-
nificant disability or incapacity.
Safety-related data will be analyzed with respect to fre-
quency of:
• Serious adverse events and adverse events stratified acor-
rding to the organ-systems
• Adverse events stratified by severity
• Adverse events stratified by causality
Statistical analysis
The alternative hypothesis for the primary endpoint is
that there is no relevant difference in the postsurgical pain
outcome. Postsurgical pain has two essential compo-
nents: The pain experienced by patients measured on the
second postoperative day by VAS and the amount of anal-
gesic drug required (piritramide [mg/h]). Thus, two equiv-
alence tests have to be analyzed confirmatively. For both
tests the confidence interval approach will be used. The
global significance level must be 0.05. The Bonferroni-
Holm Procedure will be used to analyze this multiple test
problem. Since the randomization will be stratified by
operation class, the analysis also has to be stratified. Thus,
an analysis of variance with the two factors incision type
and operation class will be performed. A switch to a supe-
riority design is planned if one of the equivalence tests
does not give a significant result.
The analysis will be performed on the basis of an inten-
tion-to-treat (ITT) population and with respect to ITT
principles. A patient belongs to the ITT population after
the incision. The primary endpoint will also be analyzed
on the basis of a "per protocol" population. Descriptive
methods will be used to assess the quality of data, homo-
geneity of treatment groups, endpoints, and safety of the
transverse versus the vertical approach.
Sample Size
The sample size calculation is based on α = 0.025 (Bonfer-
roni-Holm) and a desired power of 0.80. The calculation
is done separately for each primary variable using Query
Advisor Version 4.0, Statistical Solutions Ltd., Cork, Ire-
land. The maximum of the calculated sample sizes should
be taken as sample size. That result is 86 patients per
group (see below).
Experienced pain
1. Equivalence design: Assuming no difference between
group means, a standard deviation of 20 [VAS], and an
equivalence margin of δ = 10 [VAS], 86 patients per group
are required. 2. Superiority design: Assuming a minimal
clinically relevant difference of ∆ = 10 [VAS] between
group means and a standard deviation of 20 [VAS], 78
patients per group are required.
Amount of piritramide
1. Equivalence design: Assuming no difference between
group means, a standard deviation of 1 [mg/h], and an
equivalence margin of δ = 1 [mg/h], 23 patients per group
are required. 2. Superiority design: Assuming a minimal
clinically relevant difference of ∆ = 1 [mg/h] between
group means and a standard deviation of 1 [mg/h], 21
patients per group are required.
To achieve 86 patients per group, about 300 patients
should be screened.
Based on the hospital volume data of 2002, we can expect
to randomize 15 patients per month. To achieve the cal-
culated sample size the enrollment will last at least 12
months, until October 2004. The follow-up time is 1 year.
Patients excluded, not randomized, or lost to follow-up
will be documented and a specific explanation for with-
drawal from the study provided, according to the CON-
SORT statement (see Fig. 1) [15].
Randomization
Randomization lists will be generated for all strata by
computer (SAS Version 8.2, SAS Institute Inc., Cary, USA).
The sealed randomization list will be stored in the inves-
tigator file. Patients are randomized using sealed enve-
lopes in the operating room after the abdomen has been
surgically prepared.Page 4 of 7
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After surgery, in the operating room, the entire abdomen
will be covered by a wound dressing to conceal the inci-
sions type. The dressing will be first changed postopera-
tively after the primary endpoint has been assessed by a
blinded study nurse on the second postoperative day. If
necessary, the dressing will be changed before the second
postoperative day and will be done by unblinded staff not
involved in the trial with the patient blindfolded.
Treatment Program (Table 2)
Electrocauterization will be used for a standardized skin
incision in all patients. In patients randomized to the
median approach the abdominal fascia is separated in the
median line. In the transverse group the rectus muscle is
also dissected by cauterization. The time between the first
incision in the skin and the placement of the retractor will
be recorded in both groups.
The abdominal wall will be closed in a standardized way
in both groups: Four Mikulicz clamps are placed at the
edges of the abdominal fascia and a continuous, all-layer
closure technique with two Mono Plus® loops (BBD Aes-
culap, Tuttlingen, Germany) performed, starting at both
ends from the incision with a 4:1 ratio (suture : scar
length). Neither a subcutaneous closure nor a subcutane-
ous drainage is to be inserted. The skin will be closed with
skin clips. The length of the scar is measured in
centimeters.
A wound dressing is placed so as to cover almost the entire
abdomen, including the abdominal drainages.
The postoperative analgesia is standardized for both
groups: piritramide (Dipidolor®[Janssen-Cilag]) at a dos-
age of 1 mg/ml without a basic rate is administered
(patient-controlled analgesia). The dosage of the patient-
controlled boli is either 2.0 mg, 2.5 mg, or 3.0 mg given
as a single bolus over a period of 3 min. The lock-out time
is 10 min and the maximum dosage within 4 h is 45 mg.
The total amount of pain medication is documented from
the end of operation until the primary outcome
assessment.
For concomitant standardized pain treatment, metami-
zole (Novalgin®[Aventis Pharma]) 1 g is given four times
a day as i.v. infusion. If a patient has an adverse reaction
POVATI-Trial according to CONSORTFigure 1
POVATI-Trial according to CONSORT.
 To be assessed for 
eligibility (n=300)
|
                                  
Not meeting inclusion criteria (n=40) 
refusal to participate (n=20) 
other reasons (n=20) 
   
 To be randomized 
(n=220)
   
To be allocated to intervention 
(n=110) 
receive allocated intervention (n=100)
do not receive allocated intervention 
(n=10)
 To be allocated to intervention 
(n=110) 
receive allocated intervention (n=100)
do not receive allocated intervention 
(n=10)
                                ↓                             ↓
To be lost to follow-up (n=14)  To be lost to follow-up (n=14) 
                                ↓                             ↓
To be analyzed (n=86)  To be analyzed (n=86)Page 5 of 7
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gan®[Upsamedica GmbH]1 g i.v. 4 × a day given as i.v.
infusion.). The patient will not be removed from the trial
if the drug is changed.
Monitoring
An independent study nurse not involved in the trial or in
completing the CRFs will monitor the patients. The surgi-
cal monitoring, i.e., ensuring that the standardized surgi-
cal procedures are performed correctly, will be done by an
independent surgeon not involved in the trial.
Follow-up
Patients are observed for 30 days postoperatively for early-
onset complications defined as secondary endpoints. The
follow-up is completed 1 year after operation with a phys-
ical examination, including ultrasonography to exclude
an incisional hernia.
Conclusions
The POVATI trial compares the two most common inci-
sion types in general surgery. A qualitative ranking by the
patients and surgeons to assess the relevance of the pri-
mary endpoint is included. Central features of the study
design are:
1. Patient's perspective as primary endpoint
2. Detailed calculation of an adequate sample size
3. Randomization stratified for the planned surgical
procedures
4. Patient and observer blinded assessment of the primary
endpoint
Abbreviations and Definitions
CRF Case Report Form
VAS Visual Analogue Scale
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